Post
The Wall Street Journal
wsj.com
did:plc:i3fhjvvkbmirhyu4aeihhrnv
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion. on.wsj.com/4aeK47m
https://on.wsj.com/4aeK47m
2026-01-25T19:32:37.251Z